PCI The Journeys Within
CPHI 2026 – 23/07/2026

Current Edition

ramusmedical
Asia Pacific

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis

Servier, an independent international pharmaceutical company, and the company Galapagos NV announce the start of a global Phase 2 trial with S201086/GLPG1972 in knee...
Continue Reading →
Europe

Study using DFMO shows positive results for children with high risk neuroblastoma

A paper published September 27 in Scientific Reports shows the positive results of a phase II clinical trial using the oral medication DFMO to prevent relapse in chil...
Continue Reading →
news

AbbVie Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse Large B-Cell Lymphoma and Ongoing Ibrutinib Clinical Program

AbbVie , a research-based global biopharmaceutical company, announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA®) in untreated diffuse large B-c...
Continue Reading →
news

Pivotal Clinical Trial Costs Estimated at $19 Million

A new analysis has found it costs an average of $19 million to get new drugs through pivotal clinical trials and onto the market. Researchers at the Institute for Saf...
Continue Reading →
Europe

Human clinical trial of investigational calcification inhibitor generates promising results

Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis. A first-time-in-human clinical trial of an investigati...
Continue Reading →
news

New cancer vaccine may tackle HER2-positive tumors

New research shows that a new cancer vaccine may be effective for treating a range of HER2-positive cancers, including the more aggressive HER2-positive breast cancer...
Continue Reading →
Asia Pacific

Blockchain to Combat Type 2 Diabetes Epidemic in India

Genomics pioneer Shivom hopes to transform diagnosis and treatment of a disease that’s pervasive in the country. London, UK - 25 September 2018: A pioneering diabetes...
Continue Reading →
Europe

Catalent Selected to Provide Oral Delivery Systems for GB Sciences’ Proprietary Parkinson’s Disease Therapies

GB Sciences and Catalent tackle the first-ever formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson’s disease. SWINDO...
Continue Reading →
Europe

New inflammatory biomarker predicts elevated thrombosis risk in cancer patients

(Vienna, 26 September 2018) Cancer patients are known to have an increased risk of thrombosis. As part of the CATS study, MedUni Vienna researchers have now investiga...
Continue Reading →
Europe

Psychotropic polypharmacy is common in Alzheimer’s disease

Up to half of people with Alzheimer’s disease (AD) use a psychotropic drug, and one in five uses two or more psychotropics concomitantly, according to a study conduct...
Continue Reading →
Quotient
CPHI 2026 – 20/07/2026